Expression of EGFR, HER-2,VEGF in tumour tissues and their directive significance for the molecular targeting therapy of colorectal carcinoma
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 18
- DOI:
- 10.3969/j.issn.1009-3079.2009.18.007
- Key Word:
- 结直肠肿瘤;表皮生长因子受体;人表皮生长因子受体-2;血管内皮生长因子;免疫组织化学;Colorectal carcinoma;Epidermal growth factor receptor;Human epidermal receptor-2;Vascular endothelial growth factor;Immunohistochemistry
Abstract： AIM: To detect the characteristics of epidermal growth factor receptor (EGFR),human epidermal receptor-2 (HER-2) and vascular endothelial growth factor (VEGF) expression in colorectal carcinoma (CRC) tumor tissues, and to analyze their directive significance for the molecular targeting therapy of colorectal carcinoma (CRC). METHODS: Seventy eight patients with CRC were randomly selected, who underwent radical surgery in the department of general surgery at our hospital from May 2005 to March 2009. The SP Immunohistochemical staining was used to detect EGFR, HER-2 and VEGF protein expression in 78 CRC tumor tissue samples. And their corresponding clinical data were analysed retrospectively. RESULTS: The expression rates of EGFR, HER-2 and VEGF protein in CRC tumour tissue were 38.5% (30/78), 53.8% (42/78) and 41.0% (32/78). Positive rates of EGFR, HER-2 and VEGF protein were closely relevant to the tumour size, knubbly invasive depth and lymph node metastasis; but not to the patient's sex, age, tumor site or histology grade. There was a stable positive relationship among EGFR, HER-2 and VEGF expression in CRC tumour tissue samples. The related coefficients were 0.421, 0.484 and 0.469 respectively (P = 0.019, 0.012 and 0.016). CONCLUSION: The present study demonstrates that the EGFR, HER-2 and VEGF expression participate in the development, invasion and metastasis process of CRC. Their joint detection can be looked as an important symbol for judging the prognosis of CRC, screening the high-risk metastasis patients and guiding the molecular targeting therapy of colorectal carcinoma.
- [1]付建华,赵曼,胡国强,等.EGFR和E-cadherin与肿瘤的发生发展及其调控机制的研究进展[J].2008,(1).
- [2]Jin Cheon Kim,Seon Young Kim,Seon Ae Roh,etc.Gene expression profiling: Canonical molecular changes and clinicopathological features in sporadic colorectal cancers[J].2008,(43).
- [3]Markus Moehler,Christian Frings,Annett Mueller,etc.VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab[J].2008,(26).
- [4]袁慕知,邹征云,刘宝瑞.西妥昔单抗治疗结直肠癌的进展[J].2007,(7).
- [5]吴晴,李兆申.消化系统肿瘤的分子靶向治疗[J].2008,(32).
- [6]冯俊,吴云飞,徐惠绵.EGFR、VEGF表达与大肠癌淋巴结及肝转移的相关性[J].2008,(3).
- [7]Marie-Pierre Buisine,Agnès Wacrenier,Christophe Mariette,etc.Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers[J].2008,(7).
- [8]施凉潘,潘运龙.结直肠癌血管形成、侵袭和转移的研究进展[J].2008,(1).
- [9]杜伟,王杰军,何金.大肠癌中EGFR、c-erbB-2及VEGF的表达与临床病理特征的关系[J].2008,(3).
- [10]欧希龙,关云艳,颜芳,等.血管内皮生长因子165基因对人胃癌细胞凋亡的影响及机制[J].2008,(3).
- [11]刘磊,白玉贤.EGFR靶向药物治疗胃肠道肿瘤的新进展[J].2008,(4).
- [12]郁宝铭.结直肠癌分子靶向治疗药物研究现状[J].2008,(33).
- [13].Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma[J].2008,(46).
- [14]刘宝全,范圣第.EGFR信号转导机制及靶向治疗[J].2008,(1).
- [15]廖旺军,石敏,郑大勇,等.结直肠癌原发灶与转移灶中EGFR表达的免疫组化研究[J].2008,(1).
- [16]Crippa S,Mazzucchelli L,Frattini M,etc.Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.[J].2009,100(7).
- [17]Leonard, Saltz.Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?).[J].2008,2(4 Suppl).
- [18]Johnston JB,Navaratnam S,Pitz MW,etc.Targeting the EGFR pathway for cancer therapy.[J].2006,13(29).
- [19]Adjei,A.A.,Ma,W.W..Novel agents on the horizon for cancer therapy[J].2009,59(2).
- [20]Ciardiello F,Tortora G.EGFR antagonists in cancer treatment.[J].2008,358(11).
- [21]Jain RK,Xu L.Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma.[J].2007,5(9).
- [22]Alekshun T,Garrett C.Targeted therapies in the treatment of colorectal cancers.[J].2005,12(2).
- [23]Al-Moundhri MS,Al-Shukaili A,Al-Nabhani M,etc.Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.[J].2008,14(24).
- [24]Singal R,Raez LE,Soares HP,etc.EGFR targeting of solid tumors.[J].2007,14(3).
- [25]De Maio E,Morabito A,Normanno N,etc.Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.[J].2006,11(7).